Leah Bensimon, Hui Yin, Samy Suissa, Michael N Pollak, Laurent Azoulay
BACKGROUND: Given the conflicting results from observational studies, we assessed whether the use of metformin after a prostate cancer diagnosis is associated with a decreased risk of cancer-specific and all-cause mortality. METHODS: This study was conducted linking four databases from the United Kingdom. A cohort of men newly diagnosed with nonmetastatic prostate cancer with a history of treated type II diabetes, between April 1, 1998 and December 31, 2009, was followed until October 1, 2012...
October 2014: Cancer Epidemiology, Biomarkers & Prevention